Last reviewed · How we verify
Vehicle of Bilastine Ophthalmic Solution
Vehicle of Bilastine Ophthalmic Solution is a Selective H1-receptor antagonist (antihistamine) Small molecule drug developed by Faes Farma, S.A.. It is currently in Phase 3 development for Allergic conjunctivitis, Ocular allergic inflammation.
Bilastine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in ocular tissues.
Bilastine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in ocular tissues. Used for Allergic conjunctivitis, Ocular allergic inflammation.
At a glance
| Generic name | Vehicle of Bilastine Ophthalmic Solution |
|---|---|
| Sponsor | Faes Farma, S.A. |
| Drug class | Selective H1-receptor antagonist (antihistamine) |
| Target | H1 histamine receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Allergy |
| Phase | Phase 3 |
Mechanism of action
Bilastine competitively antagonizes H1 histamine receptors on mast cells and other immune cells in the eye, preventing histamine release and reducing allergic inflammation. When formulated as an ophthalmic solution, it provides local anti-allergic effects in the conjunctiva and anterior segment of the eye. This mechanism reduces itching, redness, and other symptoms of ocular allergic conditions.
Approved indications
- Allergic conjunctivitis
- Ocular allergic inflammation
Common side effects
- Ocular irritation
- Conjunctival hyperemia
- Eye discomfort
Key clinical trials
- A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model. (PHASE3)
- A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vehicle of Bilastine Ophthalmic Solution CI brief — competitive landscape report
- Vehicle of Bilastine Ophthalmic Solution updates RSS · CI watch RSS
- Faes Farma, S.A. portfolio CI
Frequently asked questions about Vehicle of Bilastine Ophthalmic Solution
What is Vehicle of Bilastine Ophthalmic Solution?
How does Vehicle of Bilastine Ophthalmic Solution work?
What is Vehicle of Bilastine Ophthalmic Solution used for?
Who makes Vehicle of Bilastine Ophthalmic Solution?
What drug class is Vehicle of Bilastine Ophthalmic Solution in?
What development phase is Vehicle of Bilastine Ophthalmic Solution in?
What are the side effects of Vehicle of Bilastine Ophthalmic Solution?
What does Vehicle of Bilastine Ophthalmic Solution target?
Related
- Drug class: All Selective H1-receptor antagonist (antihistamine) drugs
- Target: All drugs targeting H1 histamine receptor
- Manufacturer: Faes Farma, S.A. — full pipeline
- Therapeutic area: All drugs in Ophthalmology / Allergy
- Indication: Drugs for Allergic conjunctivitis
- Indication: Drugs for Ocular allergic inflammation
- Compare: Vehicle of Bilastine Ophthalmic Solution vs similar drugs
- Pricing: Vehicle of Bilastine Ophthalmic Solution cost, discount & access